# An Evaluation of The Absolute Bioavailability of TH104

> **NCT06198686** · PHASE1 · COMPLETED · sponsor: **Tharimmune Inc** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nalmefene

## Key facts

- **NCT ID:** NCT06198686
- **Lead sponsor:** Tharimmune Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-26
- **Primary completion:** 2024-02-11
- **Final completion:** 2024-11-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06198686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06198686, "An Evaluation of The Absolute Bioavailability of TH104". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06198686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*